| Name | FTX-6058 |
|---|---|
| Synonyms | (S)-12-fluoro-4-(2-methylpyridin-3-yl)-7a,8,13,14-tetrahydro-7H-[1,2,4]triazolo[4',3':1,6]pyrido[3,2-b]benzofuro[4,3-fg][1,4]oxazonine - [AC78252] |
| Description | FTX-6058 is a potent and orally active inhibitor of Embryonic Ectoderm Development (EED). FTX-6058 can induce HbF protein expression in cell and murine models. FTX-6058 can be used for the research of select hemoglobinopathies, including sickle cell disease and β-thalassemia[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | FTX-6058 inhibits PRC2 via binding to EED, which induces robust HbF protein expression in both cell and murine models[2]. |
| References |
[1]. Boerner LK. Virtual meeting delivers first time drug structures. April 12, 2021. |
| Molecular Formula | C22H18FN5O2 |
|---|---|
| Molecular Weight | 403.41 |